Pipeline 2

PlatformProgramDomain 1Domain 2IndicationsDiscoveryPreclinicalPhase 1Phase 2Phase 3Anticipated Milestones / Status
Clinical-Stage Pipeline
ARCSL-172154SIRPαCD40LOvarian Cancer

Initial Dose Escalation Data Q4'2021

ARCSL-172154SIRPαCD40LCSCC and HNSCC(1)

Initial Dose Escalation Data 1H'2022

ARCSL-172154AML and HR-MDS(2)

IND Filings Expected Q4'2021

ARCSL-279252PD-1OX40LAdvanced Solid Tumors and Lymphoma(3)

Initial Dose Escalation Data Q4'2021

Select Preclinical-Stage Pipeline
ARC(4)SL-9258TIGITLIGHTOncology

Manufacturing

ARCSL-279137PD-14-1BBLOncology

Manufacturing

ARCMultipleUndisclosedUndisclosedAutoimmune

Non-Clinical Dev.

GADLENMultipleγδ TCRTumor AntigenOncology

Lead Candidate Selection 2021

DrugIndicationStage
SL-172154Ovarian Cancer Phase 1
SL-172154CSCC and HNSCC(1) Phase 1
SL-172154AML and HR-MDS(2) Preclinical
SL-279252Advanced Solid Tumors and Lymphoma(3) Phase 1
SL-9258Oncology Discovery
SL-279137Oncology Discovery
MultipleAutoimmune Indications
MultipleOncology Indications